| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 38 | 2024 | 1386 | 4.950 |
Why?
|
| Heart-Assist Devices | 31 | 2024 | 882 | 3.990 |
Why?
|
| Hypertension, Pulmonary | 15 | 2024 | 369 | 3.400 |
Why?
|
| Ventricular Dysfunction, Right | 6 | 2019 | 151 | 1.930 |
Why?
|
| Heart Transplantation | 15 | 2021 | 811 | 1.580 |
Why?
|
| Pulmonary Artery | 5 | 2018 | 333 | 1.340 |
Why?
|
| Echocardiography, Doppler | 4 | 2013 | 135 | 1.160 |
Why?
|
| Anticoagulants | 5 | 2021 | 457 | 1.120 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 383 | 0.920 |
Why?
|
| Hyponatremia | 1 | 2022 | 30 | 0.760 |
Why?
|
| Cardiac Catheterization | 6 | 2019 | 295 | 0.740 |
Why?
|
| Shock, Cardiogenic | 2 | 2021 | 168 | 0.710 |
Why?
|
| Arterial Pressure | 3 | 2018 | 41 | 0.700 |
Why?
|
| Hemodynamics | 10 | 2024 | 713 | 0.690 |
Why?
|
| Assisted Circulation | 1 | 2021 | 16 | 0.680 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2024 | 258 | 0.670 |
Why?
|
| Heparin | 2 | 2015 | 181 | 0.650 |
Why?
|
| Humans | 83 | 2024 | 93515 | 0.650 |
Why?
|
| Cardiac Output | 4 | 2017 | 141 | 0.600 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1229 | 0.590 |
Why?
|
| Blood Coagulation | 2 | 2018 | 90 | 0.580 |
Why?
|
| Prognosis | 11 | 2022 | 3911 | 0.570 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2021 | 256 | 0.560 |
Why?
|
| Hospital Mortality | 1 | 2021 | 482 | 0.550 |
Why?
|
| Heart Ventricles | 6 | 2020 | 650 | 0.550 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 244 | 0.550 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2020 | 145 | 0.540 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 217 | 0.530 |
Why?
|
| Patient Readmission | 2 | 2021 | 412 | 0.530 |
Why?
|
| Risk Assessment | 5 | 2019 | 2441 | 0.520 |
Why?
|
| Angina, Unstable | 2 | 2007 | 6 | 0.520 |
Why?
|
| Middle Aged | 39 | 2024 | 27573 | 0.520 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2010 | 178 | 0.520 |
Why?
|
| Male | 44 | 2024 | 44557 | 0.500 |
Why?
|
| Prospective Studies | 15 | 2020 | 4560 | 0.490 |
Why?
|
| Monitoring, Physiologic | 2 | 2015 | 262 | 0.480 |
Why?
|
| Treatment Outcome | 18 | 2022 | 9099 | 0.480 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2021 | 876 | 0.470 |
Why?
|
| Pulmonary Embolism | 2 | 2015 | 226 | 0.450 |
Why?
|
| Metolazone | 1 | 2015 | 1 | 0.450 |
Why?
|
| Chlorothiazide | 1 | 2015 | 5 | 0.450 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2015 | 4 | 0.450 |
Why?
|
| Nephrons | 1 | 2015 | 16 | 0.450 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2015 | 38 | 0.450 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2014 | 11 | 0.440 |
Why?
|
| Female | 40 | 2024 | 48702 | 0.430 |
Why?
|
| Echocardiography | 8 | 2019 | 745 | 0.430 |
Why?
|
| Stroke Volume | 8 | 2021 | 438 | 0.420 |
Why?
|
| Antihypertensive Agents | 3 | 2015 | 261 | 0.420 |
Why?
|
| Epoprostenol | 2 | 2011 | 46 | 0.410 |
Why?
|
| Coronary Artery Disease | 2 | 2010 | 375 | 0.400 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 150 | 0.400 |
Why?
|
| Exercise Test | 2 | 2014 | 152 | 0.400 |
Why?
|
| Ventricular Function, Left | 7 | 2020 | 520 | 0.400 |
Why?
|
| Retrospective Studies | 18 | 2022 | 10164 | 0.390 |
Why?
|
| Aged | 21 | 2024 | 20434 | 0.380 |
Why?
|
| Risk Factors | 13 | 2019 | 5899 | 0.370 |
Why?
|
| Long QT Syndrome | 1 | 2012 | 37 | 0.360 |
Why?
|
| Electrocardiography | 2 | 2014 | 493 | 0.350 |
Why?
|
| Incidence | 9 | 2020 | 1701 | 0.350 |
Why?
|
| Drug Resistance | 2 | 2015 | 233 | 0.350 |
Why?
|
| Catheter-Related Infections | 1 | 2011 | 24 | 0.340 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2011 | 22 | 0.340 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 452 | 0.340 |
Why?
|
| Catheterization, Peripheral | 1 | 2011 | 60 | 0.330 |
Why?
|
| Catheters | 1 | 2011 | 96 | 0.330 |
Why?
|
| Bacteremia | 1 | 2011 | 108 | 0.320 |
Why?
|
| Acute Coronary Syndrome | 1 | 2010 | 33 | 0.320 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2010 | 38 | 0.310 |
Why?
|
| Time Factors | 9 | 2019 | 5410 | 0.310 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 87 | 0.310 |
Why?
|
| Vancomycin-Resistant Enterococci | 2 | 2021 | 14 | 0.310 |
Why?
|
| Ventricular Function, Right | 1 | 2010 | 138 | 0.300 |
Why?
|
| Thrombosis | 3 | 2021 | 309 | 0.300 |
Why?
|
| Aspirin | 1 | 2010 | 167 | 0.300 |
Why?
|
| Prostaglandins | 1 | 2009 | 44 | 0.290 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2021 | 92 | 0.280 |
Why?
|
| Quality of Life | 4 | 2024 | 1780 | 0.280 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2019 | 128 | 0.280 |
Why?
|
| Acute Disease | 3 | 2021 | 841 | 0.270 |
Why?
|
| Prosthesis-Related Infections | 2 | 2020 | 61 | 0.260 |
Why?
|
| Proportional Hazards Models | 5 | 2021 | 889 | 0.260 |
Why?
|
| Hirudins | 1 | 2007 | 5 | 0.260 |
Why?
|
| Predictive Value of Tests | 7 | 2020 | 1713 | 0.250 |
Why?
|
| Blood Platelets | 1 | 2007 | 150 | 0.250 |
Why?
|
| Vasodilator Agents | 3 | 2024 | 133 | 0.240 |
Why?
|
| Follow-Up Studies | 8 | 2018 | 3830 | 0.240 |
Why?
|
| Myocardium | 5 | 2020 | 570 | 0.240 |
Why?
|
| Amyloidosis | 2 | 2021 | 129 | 0.240 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 1998 | 25 | 0.240 |
Why?
|
| Survival Rate | 5 | 2017 | 1948 | 0.230 |
Why?
|
| Administration, Intravenous | 2 | 2015 | 63 | 0.220 |
Why?
|
| Contrast Media | 2 | 2020 | 988 | 0.220 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2024 | 283 | 0.220 |
Why?
|
| Peptide Fragments | 1 | 2007 | 470 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 2 | 2018 | 111 | 0.220 |
Why?
|
| Cardiomyopathies | 2 | 2021 | 291 | 0.220 |
Why?
|
| Preoperative Care | 2 | 2018 | 406 | 0.210 |
Why?
|
| Length of Stay | 2 | 2021 | 828 | 0.210 |
Why?
|
| Graft Rejection | 3 | 2019 | 1120 | 0.200 |
Why?
|
| Cardiotonic Agents | 1 | 2024 | 88 | 0.200 |
Why?
|
| Adult | 18 | 2024 | 27918 | 0.200 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2015 | 117 | 0.190 |
Why?
|
| Self Report | 1 | 2024 | 328 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2015 | 920 | 0.190 |
Why?
|
| Postoperative Complications | 5 | 2021 | 2562 | 0.180 |
Why?
|
| Radionuclide Imaging | 2 | 2014 | 189 | 0.180 |
Why?
|
| Gadolinium | 2 | 2020 | 95 | 0.180 |
Why?
|
| Age Distribution | 2 | 2014 | 206 | 0.180 |
Why?
|
| Obesity | 2 | 2021 | 1018 | 0.180 |
Why?
|
| Blood Coagulation Factors | 2 | 2021 | 20 | 0.180 |
Why?
|
| Sodium | 1 | 2022 | 329 | 0.170 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 1917 | 0.170 |
Why?
|
| Return to Work | 1 | 2021 | 16 | 0.170 |
Why?
|
| Exercise Tolerance | 1 | 2021 | 63 | 0.170 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 85 | 0.170 |
Why?
|
| Body Fluids | 1 | 2000 | 35 | 0.160 |
Why?
|
| HIV | 1 | 2000 | 47 | 0.160 |
Why?
|
| Equipment Failure | 2 | 2020 | 118 | 0.160 |
Why?
|
| Heart Diseases | 2 | 2019 | 257 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 367 | 0.150 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 47 | 0.150 |
Why?
|
| Palliative Care | 2 | 2019 | 269 | 0.150 |
Why?
|
| United States | 5 | 2021 | 7622 | 0.150 |
Why?
|
| Early Diagnosis | 2 | 2021 | 135 | 0.150 |
Why?
|
| Blotting, Western | 1 | 2000 | 784 | 0.150 |
Why?
|
| Heart Septum | 1 | 2019 | 45 | 0.150 |
Why?
|
| Blood Pressure Monitors | 2 | 2018 | 9 | 0.150 |
Why?
|
| Prosthesis Design | 3 | 2015 | 297 | 0.150 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2019 | 85 | 0.150 |
Why?
|
| Benchmarking | 1 | 2019 | 80 | 0.140 |
Why?
|
| Heart Valve Prosthesis | 1 | 2019 | 94 | 0.140 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 24 | 0.140 |
Why?
|
| Shock | 1 | 2019 | 46 | 0.140 |
Why?
|
| Cause of Death | 2 | 2016 | 273 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 58 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 894 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 67 | 0.140 |
Why?
|
| Lung Diseases, Fungal | 1 | 1998 | 18 | 0.140 |
Why?
|
| Research Design | 2 | 2015 | 617 | 0.140 |
Why?
|
| Cardiac Volume | 2 | 2015 | 33 | 0.140 |
Why?
|
| HIV Infections | 2 | 2000 | 961 | 0.140 |
Why?
|
| Bibliometrics | 1 | 2018 | 45 | 0.140 |
Why?
|
| Aspergillosis | 1 | 1998 | 39 | 0.140 |
Why?
|
| Myocardial Contraction | 2 | 2012 | 188 | 0.140 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 71 | 0.130 |
Why?
|
| Patient Selection | 2 | 2018 | 690 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 50 | 0.130 |
Why?
|
| Shock, Septic | 1 | 2019 | 124 | 0.130 |
Why?
|
| Cardiac Tamponade | 1 | 2017 | 20 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 83 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 135 | 0.130 |
Why?
|
| Ventricular Remodeling | 2 | 2018 | 99 | 0.130 |
Why?
|
| Logistic Models | 1 | 2021 | 1243 | 0.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 187 | 0.130 |
Why?
|
| Postoperative Hemorrhage | 1 | 2017 | 49 | 0.130 |
Why?
|
| Coronary Circulation | 1 | 2017 | 95 | 0.130 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 10 | 0.130 |
Why?
|
| Antilymphocyte Serum | 1 | 2017 | 67 | 0.130 |
Why?
|
| Warfarin | 1 | 2017 | 106 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 2715 | 0.120 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 52 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 168 | 0.120 |
Why?
|
| Age Factors | 1 | 2021 | 1906 | 0.120 |
Why?
|
| ROC Curve | 1 | 2018 | 775 | 0.120 |
Why?
|
| Systole | 2 | 2020 | 83 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 291 | 0.120 |
Why?
|
| Disease Progression | 3 | 2021 | 1531 | 0.120 |
Why?
|
| Heart | 1 | 2018 | 522 | 0.110 |
Why?
|
| Mortality | 1 | 2016 | 156 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2012 | 3054 | 0.110 |
Why?
|
| Ultrasonography | 2 | 2015 | 702 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2018 | 375 | 0.110 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 990 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 960 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2018 | 364 | 0.110 |
Why?
|
| Diabetes Mellitus | 3 | 2017 | 767 | 0.110 |
Why?
|
| Urination | 1 | 2015 | 39 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 83 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2015 | 87 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 64 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2014 | 174 | 0.110 |
Why?
|
| Respiratory Function Tests | 1 | 2014 | 155 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 150 | 0.110 |
Why?
|
| Patients | 1 | 2015 | 103 | 0.100 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2014 | 15 | 0.100 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 139 | 0.100 |
Why?
|
| Uric Acid | 1 | 2014 | 137 | 0.100 |
Why?
|
| Scleroderma, Systemic | 1 | 2014 | 59 | 0.100 |
Why?
|
| Oximetry | 1 | 2014 | 90 | 0.100 |
Why?
|
| Hypertension | 2 | 2017 | 757 | 0.100 |
Why?
|
| Registries | 2 | 2021 | 990 | 0.100 |
Why?
|
| Homosexuality | 1 | 1993 | 10 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2015 | 193 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 506 | 0.100 |
Why?
|
| Physical Examination | 1 | 2014 | 144 | 0.100 |
Why?
|
| Age of Onset | 1 | 2014 | 342 | 0.100 |
Why?
|
| Equipment Design | 1 | 2015 | 416 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1103 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 1922 | 0.100 |
Why?
|
| Tricuspid Valve | 1 | 2014 | 94 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2015 | 657 | 0.100 |
Why?
|
| International Normalized Ratio | 3 | 2021 | 37 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2018 | 342 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2019 | 1931 | 0.100 |
Why?
|
| Caregivers | 1 | 2015 | 180 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 759 | 0.100 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2014 | 107 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 349 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2017 | 456 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 790 | 0.090 |
Why?
|
| Myocardial Ischemia | 1 | 2013 | 140 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2015 | 298 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2017 | 417 | 0.090 |
Why?
|
| Biomarkers | 1 | 2018 | 1910 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 238 | 0.090 |
Why?
|
| Intraoperative Care | 1 | 2012 | 88 | 0.090 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2013 | 180 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 1992 | 149 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 212 | 0.080 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2011 | 64 | 0.080 |
Why?
|
| Fibrinolytic Agents | 1 | 2013 | 239 | 0.080 |
Why?
|
| Postoperative Care | 1 | 2012 | 235 | 0.080 |
Why?
|
| Biopsy | 3 | 2019 | 1175 | 0.080 |
Why?
|
| Thrombolytic Therapy | 1 | 2013 | 254 | 0.080 |
Why?
|
| Chicago | 1 | 2015 | 1464 | 0.080 |
Why?
|
| Physical Exertion | 1 | 2010 | 38 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 493 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 579 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 429 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 339 | 0.080 |
Why?
|
| Mass Screening | 1 | 2014 | 696 | 0.080 |
Why?
|
| Illinois | 1 | 2011 | 520 | 0.080 |
Why?
|
| Coronary Disease | 1 | 2010 | 223 | 0.070 |
Why?
|
| Coronary Angiography | 1 | 2010 | 231 | 0.070 |
Why?
|
| Hospitalization | 1 | 2015 | 937 | 0.070 |
Why?
|
| Stroke | 1 | 2018 | 1079 | 0.070 |
Why?
|
| Reference Values | 1 | 2010 | 608 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2009 | 113 | 0.070 |
Why?
|
| Lung | 1 | 2014 | 1366 | 0.070 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2007 | 7 | 0.070 |
Why?
|
| Adenosine Monophosphate | 1 | 2007 | 30 | 0.070 |
Why?
|
| Heart Rate | 1 | 2010 | 505 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1914 | 0.060 |
Why?
|
| Thiophenes | 1 | 2007 | 44 | 0.060 |
Why?
|
| Partial Thromboplastin Time | 1 | 2007 | 17 | 0.060 |
Why?
|
| Diastole | 2 | 2020 | 99 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2010 | 1006 | 0.060 |
Why?
|
| Piperazines | 1 | 2007 | 284 | 0.060 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 948 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 988 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2018 | 756 | 0.050 |
Why?
|
| Ventricular Pressure | 1 | 2004 | 40 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2004 | 57 | 0.050 |
Why?
|
| Adenosine | 1 | 2007 | 275 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2004 | 92 | 0.050 |
Why?
|
| Self Care | 1 | 2024 | 167 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 1170 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3476 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 398 | 0.050 |
Why?
|
| Comorbidity | 2 | 2018 | 1007 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2001 | 73 | 0.050 |
Why?
|
| Disease Management | 1 | 2024 | 358 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2021 | 52 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2024 | 484 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 89 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2001 | 50 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2000 | 212 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2001 | 66 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2000 | 78 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2004 | 1118 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2021 | 135 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2001 | 135 | 0.040 |
Why?
|
| Algorithms | 2 | 2021 | 1953 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2001 | 285 | 0.040 |
Why?
|
| Immunocompromised Host | 2 | 2017 | 137 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 356 | 0.040 |
Why?
|
| Arterial Switch Operation | 1 | 2018 | 5 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2001 | 182 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 230 | 0.040 |
Why?
|
| Vascular Grafting | 1 | 2018 | 18 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 1847 | 0.040 |
Why?
|
| Morpholines | 1 | 2018 | 61 | 0.040 |
Why?
|
| Pulsatile Flow | 1 | 2018 | 49 | 0.040 |
Why?
|
| Amphotericin B | 1 | 1998 | 33 | 0.040 |
Why?
|
| Mitral Valve | 2 | 2013 | 225 | 0.030 |
Why?
|
| Ganciclovir | 1 | 2018 | 34 | 0.030 |
Why?
|
| Advance Care Planning | 1 | 2018 | 44 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2018 | 19 | 0.030 |
Why?
|
| Cough | 1 | 1998 | 56 | 0.030 |
Why?
|
| Allografts | 1 | 2019 | 205 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1998 | 133 | 0.030 |
Why?
|
| Blood Component Transfusion | 1 | 2017 | 12 | 0.030 |
Why?
|
| Tennessee | 1 | 2017 | 15 | 0.030 |
Why?
|
| Thermodilution | 1 | 2017 | 18 | 0.030 |
Why?
|
| Dyspnea | 1 | 1998 | 86 | 0.030 |
Why?
|
| Neutropenia | 1 | 1998 | 209 | 0.030 |
Why?
|
| Aorta, Thoracic | 1 | 2018 | 149 | 0.030 |
Why?
|
| Bacteria | 1 | 2021 | 509 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1998 | 122 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 570 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 26 | 0.030 |
Why?
|
| Fever | 1 | 1998 | 122 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 452 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2018 | 210 | 0.030 |
Why?
|
| Education | 1 | 2017 | 59 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1524 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 657 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 347 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1998 | 289 | 0.030 |
Why?
|
| Thrombectomy | 1 | 2018 | 220 | 0.030 |
Why?
|
| Encephalitozoonosis | 1 | 1996 | 1 | 0.030 |
Why?
|
| Albendazole | 1 | 1996 | 3 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 917 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 225 | 0.030 |
Why?
|
| Frailty | 1 | 2018 | 94 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 85 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2802 | 0.030 |
Why?
|
| Microsporida | 1 | 1995 | 1 | 0.030 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 1995 | 5 | 0.030 |
Why?
|
| Blood Volume Determination | 1 | 2015 | 13 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 242 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 382 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2015 | 47 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 711 | 0.030 |
Why?
|
| Critical Care | 1 | 2018 | 444 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2015 | 59 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2018 | 541 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 133 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2014 | 94 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 306 | 0.030 |
Why?
|
| Prealbumin | 1 | 2014 | 41 | 0.030 |
Why?
|
| Health Behavior | 1 | 2015 | 182 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 192 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2017 | 350 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 154 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2013 | 91 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2013 | 46 | 0.020 |
Why?
|
| Amyloid | 1 | 2014 | 104 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2013 | 69 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2014 | 160 | 0.020 |
Why?
|
| Creatinine | 1 | 2014 | 293 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2014 | 315 | 0.020 |
Why?
|
| Gastric Fundus | 1 | 1992 | 7 | 0.020 |
Why?
|
| Sexual Partners | 1 | 1993 | 106 | 0.020 |
Why?
|
| Risk-Taking | 1 | 1993 | 158 | 0.020 |
Why?
|
| Cecum | 1 | 1992 | 78 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 449 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1261 | 0.020 |
Why?
|
| Catheterization | 1 | 2013 | 218 | 0.020 |
Why?
|
| Aortic Valve | 1 | 2013 | 250 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2013 | 176 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1992 | 110 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 985 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2015 | 485 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 557 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 576 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 660 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1321 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 1546 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1995 | 1194 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 6930 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 7061 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1992 | 2585 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2004 | 896 | 0.010 |
Why?
|
| Adolescent | 2 | 2004 | 9606 | 0.010 |
Why?
|
| Anthelmintics | 1 | 1996 | 6 | 0.010 |
Why?
|
| Autopsy | 1 | 1996 | 126 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1996 | 67 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 1995 | 57 | 0.010 |
Why?
|
| Child | 1 | 2004 | 7355 | 0.010 |
Why?
|
| Intestines | 1 | 1996 | 432 | 0.010 |
Why?
|
| Animals | 1 | 1995 | 28155 | 0.000 |
Why?
|